Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Instagram Outage Disrupts Thousands of U.S. Users 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
SOUTH SAN FRANCISCO, Calif., March 05, 2018 -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a live audio webcast and conference call on Monday, March 12, 2018 at the American College of Cardiology’s 67th Annual Scientific Session & Expo (ACC.18), following the presentation of new interim data from the ongoing ANNEXA-4 Phase 3b/4 trial of the Company’s investigational Factor Xa reversal agent andexanet alfa, during the Late-Breaking Clinical Trials Session.
The conference call and live audio webcast will be hosted by Dr. C. Michael Gibson, ANNEXA-4 Executive Committee member, Harvard Medical School professor and chairman of the PERFUSE Study Group, who will provide an overview of the interim results presented during the Late-Breaking Clinical Trials Session. Dr. Gibson will be joined by Portola management for the Q&A portion of the call.
| ANNEXA-4 Late-Breaking Oral Presentation Details | |
| Session: | (409) Late-Breaking Clinical Trials Session: Interventional Cardiology |
| Title: | ANNEXA-4: Interim Report on the ANNEXA-4 Study: Andexanet for Reversal of |
| Anticoagulation in Factor Xa-Associated Acute Major Bleeding | |
| Presenter: | Stuart J. Connolly, M.D., Professor Emeritus of Medicine, McMaster University, Hamilton |
| Health Sciences | |
| Date: | Monday, March 12, 10:45 a.m. – 11:45 a.m. ET |
| Room: | ACC.18 Main Tent, Hall C |
Webcast and Conference Call Details
To access the investor webcast and presentation slides on Monday, March 12 at 12:30 p.m. ET (9:30 a.m. PT), go to the Investor Relations section of the company’s website at http://investors.portola.com. The live call can be accessed by phone by dialing (844) 452-6828 The webcast can be accessed live on the Investor Relations section of the Company's website at http://investors.portola.com. It will be archived for 30 days following the call. from the United States and Canada or 1 (765) 507-2588 internationally and using the passcode 8493604. Analysts and investors interested in attending the in-peron event in Orlando should RSVP to Cara Miller at [email protected] for additional details.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company developing product candidates that could significantly advance the fields of thrombosis and other hematologic diseases. The Company’s first medicine Bevyxxa® (betrixaban), an oral, once-daily Factor Xa inhibitor, was approved by the U.S. Food and Drug Administration in June 2017. The company is also working to advance two clinical programs for andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a SYK/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective SYK inhibitors for inflammatory conditions. For more information, visit http://www.portola.com and follow the Company on Twitter @Portola_Pharma.
Investor Contact:
Cara Miller
Portola Pharmaceuticals
[email protected]
Media Contact:
Laurie Masonson
W2O Group
[email protected]
